トップ›研究者一覧›山上紘規

研究者を探す

研究者にアプローチする
更新情報を通知する

山上紘規

徳島大学

プロフィール
教育活動
研究活動
社会活動
リサーチマップ・
Jグローバル
KAKEN
注目研究

研究者総覧で最新データを確認する

2026年4月8日更新

職名: 助教
電話: 研究者総覧に該当データはありませんでした。
電子メール: 研究者総覧に該当データはありませんでした。
学歴: 研究者総覧に該当データはありませんでした。
学位: 学士
職歴・経歴: 2022/11: 徳島大学特任助教, 病院 (-2026.3.)
2026/4: 徳島大学助教, 大学院医歯薬学研究部

専門分野・研究分野: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2026年4月8日更新

専門分野・研究分野: 研究者総覧に該当データはありませんでした。
担当経験のある授業科目: 内分泌・代謝コース (学部)
指導経験: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2026年4月8日更新

専門分野・研究分野: 研究者総覧に該当データはありませんでした。

研究テーマ: 研究者総覧に該当データはありませんでした。

著書

研究者総覧に該当データはありませんでした。

論文

MIYATAKA Kosuke, KANEKO Yohsuke, Taiki Hori, Yuki Yamaguchi, Seijiro Tsuji, Tomoyo Hara, Hiroki Yamagami, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Takeshi Harada, Hirokazu Miki, Shingen Nakamura, Itsuro Endo, Munehide Matsuhisa, Ken-ichi Matsuoka and Ken-ichi Aihara :
Red blood cell distribution width is associated with renal tubular injury in individuals with type 2 diabetes,
Journal of Diabetes Investigation, 2025.

(要約): Red blood cell distribution width (RDW) is a parameter of erythrocyte volume heterogeneity that has been traditionally used as an indicator of anemia and other hematopoietic abnormalities. Although the RDW-coefficient of variation (RDW-CV) increases in individuals with diabetes, its clinical significance in diabetic kidney disease (DKD), including glomerular and tubular injury, is unclear. Therefore, we aimed to clarify the relationship between RDW-CV and DKD indices in individuals with type 2 diabetes. This was a multicenter, retrospective, cross-sectional study. In 490 Japanese individuals with type 2 diabetes (309 men and 181 women), multiple regression analysis was performed to examine the degree of association between DKD indices (estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (uACR), log-transformed uACR (Log-uACR), urinary liver-type fatty acid-binding protein (uL-FABP)-to-creatinine ratio (uL-FABPCR), and log-transformed uL-FABPCR (Log-uL-FABPCR)) and clinical confounding factors, including RDW-CV. No significant associations were identified between RDW-CV and eGFR, uACR, or Log-uACR in either the simple or multiple linear regression analyses. However, significant and independent positive associations between RDW-CV and both uL-FABPCR and Log-uL-FABPCR were identified in multiple regression analyses (P = 0.002 and P = 0.034, respectively). Additionally, logistic regression analysis showed that RDW-CV was an aggravating factor for the incidence of advanced tubular injury [odds ratio, 1.241 (95% confidence interval: 1.010-1.520), P = 0.037]. RDW-CV was independently and positively correlated with urinary excretion of L-FABP. Therefore, RDW-CV may be a simple and useful biomarker for detecting renal tubular injury in individuals with type 2 diabetes.
(キーワード): Red blood cell distribution width / Renal tubular injury / Type 2 diabetes
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/jdi.70149
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 41021376; ● Summary page in Scopus @ Elsevier: 2-s2.0-105018330128

(DOI: 10.1111/jdi.70149, PubMed: 41021376, Elsevier: Scopus) Tomoyo Hara, Hiroki Yamagami, Ryoko Uemoto, Akiko Sekine, Yousuke Kaneko, Kohsuke Miyataka, Taiki Hori, Mayuko Shimizu, Masafumi Funamoto, Takeshi Harada, Tomoyuki Yuasa, Shingen Nakamura, Itsuro Endo, Ken-ichi Matsuoka, Yutaka Kawano, Koichi Tsuneyama, Yasumasa Ikeda and Ken-ichi Aihara :
Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice.,
Antioxidants, 14, 7, 2025.

(要約): Endothelial dysfunction contributes to the progression of metabolic-dysfunction-associated steatotic liver disease (MASLD). Pemafibrate has been shown to ameliorate MASLD in basic and clinical studies, but it is unclear whether it is also effective in the status of endothelial dysfunction. An MASLD animal model was induced in male wild-type (WT) and endothelial nitric oxide synthase (eNOS)-deficient (eNOSKO) mice by feeding them a high-fat/cholesterol/cholate diet, and they were administered either a vehicle or pemafibrate at 0.17 mg/kg/day for 10 weeks. Although pemafibrate treatment did not change plasma lipid profiles in either WT or eNOSKO mice, pemafibrate reduced plasma AST levels in both WT and eNOSKO mice compared to the levels in the vehicle-treated mice. Histopathological analysis of the liver showed that MASLD was improved in the pemafibrate-treated groups in both WT and eNOSKO mice. Compared to vehicle treatment, pemafibrate treatment significantly reduced the expression levels of hepatic NADPH oxidase subunit genes, M1 macrophages, inflammatory-cytokine-related genes and profibrotic genes in both WT and eNOSKO mice, along with reduction in hepatic oxidative stress assessed by dihydroethidium staining and 4-hydroxynonenal protein levels. Thus, pemafibrate ameliorated MASLD with reduction in oxidative stress and inflammation even in vascular endothelial dysfunction.
(徳島大学機関リポジトリ): ● Metadata: 2013384
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/antiox14070891
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 40722995; ● Summary page in Scopus @ Elsevier: 2-s2.0-105011498553

(徳島大学機関リポジトリ: 2013384, DOI: 10.3390/antiox14070891, PubMed: 40722995, Elsevier: Scopus) Yousuke Kaneko, Yutaka Kawano, Saki Kawata, Kensuke Mori, Minae Hosoki, Taiki Hori, Kohsuke Miyataka, Seijiro Tsuji, Tomoyo Hara, Hiroki Yamagami, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Takeshi Harada, Hirokazu Miki, Shingen Nakamura, Itsuro Endo, Munehide Matsuhisa, Ken-ichi Matsuoka and Ken-ichi Aihara :
Mean Corpuscular Volume Is Correlated with Liver Fibrosis Defined by Noninvasive Blood Biochemical Indices in Individuals with Metabolic Disorders Aged 60 Years or Older.,
Journal of Clinical Medicine, 14, 13, 4680, 2025.

(要約): Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) causes progressive liver fibrosis. Although erythrocyte mean corpuscular volume (MCV) has been shown to have a positive correlation with all-cause mortality, the association between MCV and the development of MASLD has not been fully elucidated. Here, we examined the clinical significance of the association between MCV and MASLD. Methods: A cross-sectional study was carried out in 1009 Japanese individuals (including 186 individuals aged < 60 years and 823 individuals aged 60 years) with metabolic disorders. The relationships between MCV and noninvasive clinical markers of liver fibrosis, including fibrosis-4 (FIB-4) index, aspartate aminotransferase-to-platelet ratio index (APRI), and non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS), were statistically evaluated. Results: Using multiple and logistic regression analyses in overall subjects, it was found that MCV was positively and independently associated with the values of FIB-4 index, APRI, NFS, and the prevalence of liver fibrosis defined by each index. However, the associations between the MCV value and MASLD indices were found to be positive in subjects aged 60 years but not in those aged < 60 years. Conclusions: MCV might be a simple and useful biomarker for the development of MASLD in the elderly.
(徳島大学機関リポジトリ): ● Metadata: 2013385
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/jcm14134680
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 40649054; ● Summary page in Scopus @ Elsevier: 2-s2.0-105019691192

(徳島大学機関リポジトリ: 2013385, DOI: 10.3390/jcm14134680, PubMed: 40649054, Elsevier: Scopus) Tomoyo Hara, Takeshi Watanabe, Hiroki Yamagami, Kosuke Miyataka, Saya Yasui, Takahito Asai, Yohsuke Kaneko, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Soichi Honda, Akira Kondo, Munehide Matsuhisa and Ken-ichi Aihara :
Development of Liver Fibrosis Represented by the Fibrosis-4 Index Is a Specific Risk Factor for Tubular Injury in Individuals with Type 2 Diabetes,
Biomedicines, 12, 8, 1789, 2024.

(要約): Although hyperglycemia and hypertension are well-known risk factors for glomerular injury in individuals with type 2 diabetes (T2D), specific risk factors for tubular injury remain unclear. We aimed to clarify the differences between risk factors for glomerular injury and risk factors for tubular injury in individuals with T2D. We categorized 1243 subjects into four groups based on urinary biomarkers, including the albumin-to-creatinine ratio (uACR) and L-type fatty acid-binding protein-to-creatinine ratio (uL-ABPCR) as a normal (N) group (uACR < 30 mg/gCr and uL-FABPCR < 5 μg/gCr; n = 637), a glomerular specific injury (G) group (uACR ≥ 30 mg/gCr and uL-FABPCR < 5 μg/gCr; n = 248), a tubular specific injury (T) group (uACR < 30 mg/gCr and uL-FABPCR ≥ 5 μg/gCr; n = 90), and a dual injury (D) group (uACR ≥ 30 mg/gCr and uL-FABPCR ≥ 5 μg/gCr; n = 268). Logistic regression analysis referencing the N group revealed that BMI, current smoking, and hypertension were risk factors for the G group, creatinine (Cr) and Fibrosis-4 (FIB-4) index were risk factors for the T group, and BMI, hypertension, HbA1c, Cr, and duration of diabetes were risk factors for the D group. While hypertension was a distinct specific risk factor for glomerular injury, the FIB-4 index was a specific contributor to the prevalence of tubular injury. On the other hand, the logistic regression analysis revealed that the hepatic steatosis index (HSI) did not show any significant association with the G group, T group, or D group. Taken together, the development of liver fibrosis rather than liver steatosis is an inherent threat relating to tubular injury in individuals with T2D.
(徳島大学機関リポジトリ): ● Metadata: 2012770
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/biomedicines12081789
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39200252; ● Summary page in Scopus @ Elsevier: 2-s2.0-85202596205

(徳島大学機関リポジトリ: 2012770, DOI: 10.3390/biomedicines12081789, PubMed: 39200252, Elsevier: Scopus) Mai Kanai, Byambasuren Ganbaatar, Itsuro Endo, Yukiyo Ohnishi, Jumpei Teramachi, Hirofumi Tenshin, Yoshiki Higa, Masahiro Hiasa, Yukari Mitsui, Tomoyo Hara, Shiho Masuda, Hiroki Yamagami, Yuki Yamaguchi, Ken-ichi Aihara, Mayu Sebe, Rie Tsutsumi, Hiroshi Sakaue, Toshio Matsumoto and Masahiro Abe :
Inflammatory Cytokine-Induced Muscle Atrophy and Weakness Can Be Ameliorated by an Inhibition of TGF-β-Activated Kinase-1,
International Journal of Molecular Sciences, 25, 11, 5715, 2024.

(要約): Chronic inflammation causes muscle wasting. Because most inflammatory cytokine signals are mediated via TGF-β-activated kinase-1 (TAK1) activation, inflammatory cytokine-induced muscle wasting may be ameliorated by the inhibition of TAK1 activity. The present study was undertaken to clarify whether TAK1 inhibition can ameliorate inflammation-induced muscle wasting. SKG/Jcl mice as an autoimmune arthritis animal model were treated with a small amount of mannan as an adjuvant to enhance the production of TNF-α and IL-1β. The increase in these inflammatory cytokines caused a reduction in muscle mass and strength along with an induction of arthritis in SKG/Jcl mice. Those changes in muscle fibers were mediated via the phosphorylation of TAK1, which activated the downstream signaling cascade via NF-κB, p38 MAPK, and ERK pathways, resulting in an increase in myostatin expression. Myostatin then reduced the expression of muscle proteins not only via a reduction in MyoD1 expression but also via an enhancement of Atrogin-1 and Murf1 expression. TAK1 inhibitor, LL-Z1640-2, prevented all the cytokine-induced changes in muscle wasting. Thus, TAK1 inhibition can be a new therapeutic target of not only joint destruction but also muscle wasting induced by inflammatory cytokines.
(キーワード): Animals / MAP Kinase Kinase Kinases / Muscular Atrophy / Mice / 細胞質分裂 (cytokinesis) / Muscle Weakness / Myostatin / Muscle Proteins / Tumor Necrosis Factor-alpha / NF-kappa B / 炎症 (inflammation) / シグナル伝達 (signal transduction) / Tripartite Motif Proteins / Disease Models, Animal / Interleukin-1beta / リン酸化 (phosphorylation) / Muscle, Skeletal / Zearalenone
(徳島大学機関リポジトリ): ● Metadata: 2013497
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/ijms25115715
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38891908; ● Summary page in Scopus @ Elsevier: 2-s2.0-85195855255

(徳島大学機関リポジトリ: 2013497, DOI: 10.3390/ijms25115715, PubMed: 38891908, Elsevier: Scopus) Taiki Hori, Taro Shimizu, Hidenori ANDO, Naoto Okada, Hiroki Yamagami, Saya Yasui, Minae Hosoki, Akihiro Tojima, Toshiki Otoda, Tomoyuki Yuasa, Ken-ichi Aihara, Makoto Takishita, Sumiko Yoshida, Masahiro Abe, Tatsuhiro Ishida and Shingen Nakamura :
Humoral immune response against SARS-CoV-2 and polyethylene glycol elicited by anti-SARS-CoV-2 mRNA vaccine, and effect of pre-existing anti-polyethylene glycol antibody in patients with hematological and autoimmune diseases.,
Heliyon, 10, 10, e31489, 2024.

(要約): The effects of vaccination are modified by hematological and autoimmune diseases and/or treatment. Anti-SARS-CoV-2 mRNA vaccine contains polyethylene glycol (PEG), it is largely unknown whether PEG influences the effects of vaccination or induces a humoral response. This study examined whether anti-PEG antibodies before vaccination (pre-existing) influenced the acquisition of SARS-CoV-2 antibodies and evaluated the relationship between the development of anti-SARS-CoV-2 antibodies and anti-PEG antibodies after SARS-CoV-2 vaccination in hematological and autoimmune diseases. Anti-SARS-CoV-2 antibody IgG, anti-PEG IgG, and IgM titers were evaluated in patients with hematological and autoimmune diseases after the second dose of BNT162B2. Anti-PEG IgG and IgM titers were also measured before vaccination to examine changes after vaccination and the relationship with vaccine efficacy. In patients with hematological (n = 182) and autoimmune diseases (n = 96), anti-SARS-CoV-2 and anti-PEG antibody titers were evaluated after a median of 33 days from 2nd vaccination. The median anti-SARS-CoV-2 antibody titers were 1901 AU/mL and 3832 AU/mL in patients with hematological and autoimmune disease, respectively. Multiple regression analysis showed that age and days from 2nd vaccination were negatively associated with anti-SARS-CoV-2 antibody titers. Anti-CD20 antibody treatment was negatively correlated with anti-SARS-CoV-2 antibody titers in hematological disease, and C-reactive protein (CRP) was positively correlated with anti-SARS-CoV-2 antibody titers in autoimmune disease. Baseline anti-PEG antibody titers were significantly higher in patients with autoimmune disease but were not correlated with anti-SARS-CoV-2 antibody titers. Patients with increased anti-PEG IgG acquired higher anti-SARS-CoV-2 antibody titers in patients with autoimmune disease. Anti-SARS-CoV-2 antibody acquisition was suboptimal in patients with hematological disease, but both anti-SARS-CoV-2 antibody and anti-PEG IgG were acquired in patients with autoimmune disease, reflecting robust humoral immune response. Pre-existing anti-PEG antibody titers did not affect anti-SARS-CoV-2 antibody acquisition.
(徳島大学機関リポジトリ): ● Metadata: 2012299
(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.heliyon.2024.e31489
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38813140; ● Summary page in Scopus @ Elsevier: 2-s2.0-85193252659

(徳島大学機関リポジトリ: 2012299, DOI: 10.1016/j.heliyon.2024.e31489, PubMed: 38813140, Elsevier: Scopus) Mariko Aoyama, Naoya Kawakita, Tomoyo Hara, Hiroki Yamagami, Taihei Takeuchi, Naoki Miyamoto, Shin-ichi Sakamoto, Seiya Inoue, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa :
Silicone stent placement for tracheal stenosis induced by a giant goiter due to Graves disease: a case report,
Gland Surgery, 13, 4, 578-583, 2024.

(要約): Although thyroid tumors with tracheal stenosis are occasionally encountered, severe tracheal stenosis caused by benign thyroid tumors is rare. We herein describe a case in which a silicone tracheal stent was placed for severe tracheal stenosis induced by a giant goiter due to Graves' disease. A 93-year-old woman had been receiving thiamazole treatment for Graves' disease with a thyroid goiter for 32 years. She emergently presented to the hospital with sudden difficulty breathing and the temporary loss of consciousness. Although marked stridor was heard, the patient's respiratory status was stable in the first visit. Computed tomography revealed a giant thyroid goiter that extended to the mediastinum. The trachea was compressed by the sternal notch and thyroid gland, resulting in severe stenosis, and the tracheal lumen was only 1 mm. Surgical thyroidectomy was expected to be difficult due to the high risk of complications associated with the large size of the goiter and advanced age of the patient. Therefore, we decided to place a tracheal stent. A silicone stent (Dumon tube) was inserted into the site of tracheal stenosis under general anesthesia. After stent placement, respiratory distress symptoms improved, and no complications were observed. Three months after stent placement, the stent opening side was narrowed due to defective granulation and, thus, was cauterized with argon plasma coagulation. We encountered a patient who was treated by tracheal silicone stent placement for severe tracheal stenosis induced by a giant goiter due to Graves' disease. A silicone stent effectively secures the airway for benign thyroid tumors that cause severe airway stenosis.
(徳島大学機関リポジトリ): ● Metadata: 2012795
(出版サイトへのリンク): ● Publication site (DOI): 10.21037/gs-23-499
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38720672; ● Summary page in Scopus @ Elsevier: 2-s2.0-85192721455

(徳島大学機関リポジトリ: 2012795, DOI: 10.21037/gs-23-499, PubMed: 38720672, Elsevier: Scopus) Minae Hosoki, Taiki Hori, KANEKO Yohsuke, Kensuke Mori, Saya Yasui, Seijiro Tsuji, Hiroki Yamagami, Saki Kawata, Tomoyo Hara, Shiho Masuda, Yukari Mitsui, Kiyoe Kurahashi, Takeshi Harada, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara :
Causes of In-Hospital Death and Pharmaceutical Associations with Age of Death during a 10-Year Period (2011-2020) in Individuals with and without Diabetes at a Japanese Community General Hospital.,
Journal of Clinical Medicine, 13, 5, 1283, 2024.

(要約): Since diabetes and its complications have been thought to exaggerate cardiorenal disease, resulting in a short lifespan, we investigated causes of death and lifespans in individuals with and without diabetes at a Japanese community general hospital during the period from 2011 to 2020. Causes of death and age of death in individuals with and those without diabetes were compared, and associations between medications used and age of death were statistically analyzed. A total of 2326 deaths were recorded during the 10-year period. There was no significant difference between the mean ages of death in individuals with and those without diabetes. Diabetic individuals had higher rates of hepato-pancreatic cancer and cardio-renal failure as causes of death. The prescription rates of antihypertensives, antiplatelets, and statins in diabetic individuals were larger than those in non-diabetic individuals. Furthermore, the use of sulfonyl urea or glinides and insulin was independently and inversely associated with the age of death. In conclusion, individuals with diabetes were treated with comprehensive pharmaceutical interventions and had life spans comparable to those of individuals without diabetes. This study's discovery of an inverse relationship between the use of insulin secretagogues or insulin and the age of death suggests that the prevention of life-threatening hypoglycemia is crucial for individuals with diabetes.
(徳島大学機関リポジトリ): ● Metadata: 2011959
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/jcm13051283
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38592103; ● Summary page in Scopus @ Elsevier: 2-s2.0-85187472209

(徳島大学機関リポジトリ: 2011959, DOI: 10.3390/jcm13051283, PubMed: 38592103, Elsevier: Scopus) Kimiko Sogabe, Shingen Nakamura, Yoshiki Higa, Hirokazu Miki, Asuka Oda, Tomoko Maruhashi, Ryohei Sumitani, Masahiro Oura, Mamiko Takahashi, Masafumi Nakamura, Yusaku Maeda, Tomoyo Hara, Hiroki Yamagami, Shiroh Fujii, Kumiko Kagawa, Shuji Ozaki, Kiyoe Kurahashi, Itsuro Endo, Ken-ichi Aihara, Emiko Nakaue, Masahiro Hiasa, Jumpei Teramachi, Takeshi Harada and Masahiro Abe :
Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.,
International Journal of Hematology, 119, 3, 303-315, 2024.

(要約): Resistance to proteasome inhibitors (PIs) has emerged as an important clinical issue. We investigated the mechanisms underlying multiple myeloma (MM) cell resistance to PIs. To mimic their pharmacokinetic/pharmacodynamic (PK/PD) profiles, MM cells were treated with bortezomib and carfilzomib for 1 h at concentrations up to 400 and 1,000 nM, respectively. Susceptibility to these PIs markedly varied among MM cell lines. Pulsatile treatments with PIs suppressed translation, as demonstrated by incorporation of puromycin at 24 h in PI-susceptible MM.1S cells, but not PI-resistant KMS-11 cells. Inhibition of β5 subunit activity decreased at 24 h in KMS-11 cells, even with the irreversible PI carfilzomib, but not under suppression of protein synthesis with cycloheximide. Furthermore, the proteasome-degradable pro-survival factors PIM2 and NRF2 acutely accumulated in MM cells subjected to pulsatile PI treatments. Accumulated NRF2 was trans-localized into the nucleus to induce the expression of its target gene, HMOX1, in MM cells. PIM and Akt inhibition restored the anti-MM effects of PIs, even against PI-resistant KMS-11 cells. Collectively, these results suggest that increased synthesis of β5 proteasome subunit and acute accumulation of PIM2 and NRF2 reduce the anti-MM effects of PIs.
(キーワード): Humans / Proteasome Inhibitors / NF-E2-Related Factor 2 / Multiple Myeloma / Proteasome Endopeptidase Complex / Drug Resistance, Neoplasm / Cell Line, Tumor / Bortezomib / Antineoplastic Agents / Proto-Oncogene Proteins / Protein Serine-Threonine Kinases
(徳島大学機関リポジトリ): ● Metadata: 2012078
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12185-023-03705-9
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38245883; ● Search Scopus @ Elsevier (PMID): 38245883; ● Search Scopus @ Elsevier (DOI): 10.1007/s12185-023-03705-9

(徳島大学機関リポジトリ: 2012078, DOI: 10.1007/s12185-023-03705-9, PubMed: 38245883) Hiroki Yamagami, Tomoyo Hara, Saya Yasui, Minae Hosoki, Taiki Hori, Yousuke Kaneko, Yukari Mitsui, Kiyoe Kurahashi, Takeshi Harada, Sumiko Yoshida, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara :
Cross-Sectional and Longitudinal Associations between Skin Autofluorescence and Tubular Injury Defined by Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in People with Type 2 Diabetes.,
Biomedicines, 11, 11, 3020, 2023.

(要約): It has previously been unclear whether the accumulation of advanced glycation end products, which can be measured using skin autofluorescence (SAF), has a significant role in diabetic kidney disease (DKD), including glomerular injury and tubular injury. This study was therefore carried out to determine whether SAF correlates with the progression of DKD in people with type 2 diabetes (T2D). In 350 Japanese people with T2D, SAF values were measured using an AGE Reader®, and both urine albumin-to-creatinine ratio (uACR), as a biomarker of glomerular injury, and urine liver-type fatty acid-binding protein (uLFABP)-to-creatinine ratio (uL-FABPCR), as a biomarker of tubular injury, were estimated as indices of the severity of DKD. Significant associations of SAF with uACR (p < 0.01), log-transformed uACR (p < 0.001), uL-FABPCR (p < 0.001), and log-transformed uL-FABPCR (p < 0.001) were found through a simple linear regression analysis. Although SAF was positively associated with increasing uL-FABPCR (p < 0.05) and increasing log-transformed uL-FABPCR (p < 0.05), SAF had no association with increasing uACR or log-transformed uACR after adjusting for clinical confounding factors. In addition, the annual change in SAF showed a significant positive correlation with annual change in uL-FABPCR regardless of confounding factors (p = 0.026). In conclusion, SAF is positively correlated with uL-FABP but not with uACR in people with T2D. Thus, there is a possibility that SAF can serve as a novel predictor for the development of diabetic tubular injury.
(キーワード): skin autofluorescence / type 2 diabetes / diabetic kidney disease / albuminuria / tubular injury / L-FABP
(徳島大学機関リポジトリ): ● Metadata: 2011823
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/biomedicines11113020
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38002020; ● CiNii @ 国立情報学研究所 (CRID): 1050867133848050816; ● Summary page in Scopus @ Elsevier: 2-s2.0-85178346619

(徳島大学機関リポジトリ: 2011823, DOI: 10.3390/biomedicines11113020, PubMed: 38002020, CiNii: 1050867133848050816, Elsevier: Scopus) Saya Yasui, Yousuke Kaneko, Hiroki Yamagami, Minae Hosoki, Taiki Hori, Akihiro Tani, Tomoyo Hara, Kiyoe Kurahashi, Takeshi Harada, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Hiroyasu Mori, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Takeshi Soeki and Ken-ichi Aihara :
Dehydroepiandrosterone Sulfate, an Adrenal Androgen, Is Inversely Associated with Prevalence of Dynapenia in Male Individuals with Type 2 Diabetes.,
Metabolites, 13, 11, 1129, 2023.

(要約): Dehydroepiandrosterone sulfate (DHEAS) is thought to be associated with life expectancy and anti-aging. Although skeletal muscle disorders are often found in diabetic people, the clinical significance of DHEAS in skeletal muscle remains unclear. Therefore, we aimed to determine whether DHEAS is associated with the development of skeletal muscle disorders in individuals with type 2 diabetes (T2D). A cross-sectional study was conducted in 361 individuals with T2D. Serum DHEAS levels, skeletal muscle mass index (SMI), handgrip strength (HS), and gait speed (GS) were measured in the participants. Pre-sarcopenia, sarcopenia, and dynapenia were defined according to the definitions of the AWGS 2019 criteria. DHEAS level was positively associated with HS but not with SMI or GS after adjustment of confounding factors. Multiple logistic regression analyses in total subjects showed that DHEAS level had an inverse association with the prevalence of dynapenia but not with the prevalence of pre-sarcopenia or sarcopenia. Furthermore, a significant association between DHEAS level and dynapenia was found in males but not in females. ROC curve analysis indicated that cutoff values of serum DHEAS for risk of dynapenia in males was 92.0 μg/dL. Therefore, in male individuals with T2D who have low serum levels of DHEAS, adequate exercise might be needed to prevent dynapenia.
(徳島大学機関リポジトリ): ● Metadata: 2011822
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/metabo13111129
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37999225; ● CiNii @ 国立情報学研究所 (CRID): 1050585658871340800; ● Summary page in Scopus @ Elsevier: 2-s2.0-85178271509

(徳島大学機関リポジトリ: 2011822, DOI: 10.3390/metabo13111129, PubMed: 37999225, CiNii: 1050585658871340800, Elsevier: Scopus) Masahiro Oura, Takeshi Harada, Asuka Oda, Jumpei Teramachi, Atsushi Nakayama, Ryohei Sumitani, Yusuke Inoue, Yusaku Maeda, Kimiko Sogabe, Maruhashi Tomoko, Mamiko Takahashi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Shingen Nakamura, Tomoyo Hara, Hiroki Yamagami, Kiyoe Kurahashi, Itsuro Endo, Hiroo Hasegawa, Hiroshi Fujiwara and Masahiro Abe :
Therapeutic efficacy of the resorcylic acid lactone LL-Z1640-2 for adult T-cell leukaemia/lymphoma,
eJHaem, 4, 3, 667-678, 2023.

(要約): Adult T-cell leukaemia/lymphoma (ATL) remains incurable. The NF-κB and interferon regulatory factor 4 (IRF4) signalling pathways are among the critical survival pathways for the progression of ATL. TGF-β-activated kinase 1 (TAK1), an IκB kinase-activating kinase, triggers the activation of NF-κB. The resorcylic acid lactone LL-Z1640-2 is a potent irreversible inhibitor of TAK1/extracellular signal-regulated kinase 2 (ERK2). We herein examined the therapeutic efficacy of LL-Z1640-2 against ATL. LL-Z1640-2 effectively suppressed the in vivo growth of ATL cells. It induced in vitro apoptosis and inhibited the nuclear translocation of p65/RelA in ATL cells. The knockdown of strongly induced ATL cell death while downregulating MYC. LL-Z1640-2 as well as the NF-κB inhibitor BAY11-7082 decreased the expression of IRF4 and MYC at the protein and mRNA levels, indicating the suppression of the NF-κB-IRF4-MYC axis. The treatment with LL-Z1640-2 also mitigated the phosphorylation of p38 MAPK along with the expression of CC chemokine receptor 4. Furthermore, the inhibition of STAT3/5 potentiated the cytotoxic activity of LL-Z1640-2 against IL-2-responsive ATL cells in the presence of IL-2. Therefore, LL-Z1640-2 appears to be an effective treatment for ATL. Further studies are needed to develop more potent compounds that retain the active motifs of LL-Z1640-2.
(出版サイトへのリンク): ● Publication site (DOI): 10.1002/jha2.758
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37601887; ● Search Scopus @ Elsevier (PMID): 37601887; ● Search Scopus @ Elsevier (DOI): 10.1002/jha2.758

(DOI: 10.1002/jha2.758, PubMed: 37601887) Shiho Masuda, Tomoyo Hara, Hiroki Yamagami, Yukari Mitsui, Kiyoe Kurahashi, Sumiko Yoshida, Takeshi Harada, Toshiki Otoda, Tomoyuki Yuasa, Shingen Nakamura, Akio Kuroda, Itsuro Endo, Toshio Matsumoto, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara :
Vascular Endothelial Function Is Associated with eGFR Slope in Female and Non-Smoking Male Individuals with Cardiovascular Risk Factors: A Pilot Study on the Predictive Value of FMD for Renal Prognosis.,
Journal of Atherosclerosis and Thrombosis, 2023.

(要約): In individuals with cardiovascular risk factors, evaluation of vascular endothelial function enables prediction of renal prognosis in females and non-smoking males.
(徳島大学機関リポジトリ): ● Metadata: 2011012
(出版サイトへのリンク): ● Publication site (DOI): 10.5551/jat.63987
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37081616; ● Search Scopus @ Elsevier (PMID): 37081616; ● Search Scopus @ Elsevier (DOI): 10.5551/jat.63987

(徳島大学機関リポジトリ: 2011012, DOI: 10.5551/jat.63987, PubMed: 37081616) Emiko Nakaue, Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Takeshi Harada, Asuka Oda, Yusuke Inoue, Sou Shimizu, Yoshiki Higa, Kimiko Sogabe, Masahiro Oura, Tomoyo Hara, Ryohei Sumitani, Tomoko Maruhashi, Hiroki Yamagami, Itsuro Endo, Eiji Tanaka and Masahiro Abe :
Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors.,
International Journal of Hematology, 2023.

(要約): Proteasome inhibitors (PIs) can preferentially restore bone in bone-defective lesions of patients with multiple myeloma (MM) who respond favorably to these drugs. Most prior in vitro studies on PIs used continuous exposure to low PI concentrations, although pharmacokinetic analysis in patients has shown that serum concentrations of PIs change in a pulsatile manner. In the present study, we explored the effects of pulsatile treatment with PIs on bone metabolism to simulate in vivo PI pharmacokinetics. Pulsatile treatment with bortezomib, carfilzomib, or ixazomib induced MM cell death but only marginally affected the viability of osteoclasts (OCs) with F-actin ring formation. Pulsatile PI treatment suppressed osteoclastogenesis in OC precursors and bone resorption by mature OCs. OCs robustly enhanced osteoblastogenesis in cocultures with OCs and MC3T3-E1 pre-osteoblastic cells, indicating OC-mediated coupling to osteoblastogenesis. Importantly, pulsatile PI treatment did not impair robust OC-mediated osteoblastogenesis. These results suggest that PIs might sufficiently reduce MM cell-derived osteoblastogenesis inhibitors to permit OC-driven bone formation coupling while suppressing OC differentiation and activity in good responders to PIs. OC-mediated coupling to osteoblastogenesis appears to be a predominant mechanism for preferential occurrence of bone regeneration at sites of osteoclastic bone destruction in good responders.
(徳島大学機関リポジトリ): ● Metadata: 2011134
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12185-023-03601-2
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37039914; ● Search Scopus @ Elsevier (PMID): 37039914; ● Search Scopus @ Elsevier (DOI): 10.1007/s12185-023-03601-2

(徳島大学機関リポジトリ: 2011134, DOI: 10.1007/s12185-023-03601-2, PubMed: 37039914) Taiki Hori, Shingen Nakamura, Hiroki Yamagami, Saya Yasui, Minae Hosoki, Tomoyo Hara, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Sumiko Yoshida, Takeshi Harada, Akio Kuroda, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara :
Phase angle and extracellular water-to-total body water ratio estimated by bioelectrical impedance analysis are associated with levels of hemoglobin and hematocrit in patients with diabetes.,
Heliyon, 9, 4, 2023.

(要約): PhA and ECW/TBW but not SMI were associated with levels of Hgb and Hct in patients with diabetes. Therefore, aberrant values of PhA and ECW/TBW suggest a risk of anemia in diabetic patients.
(徳島大学機関リポジトリ): ● Metadata: 2011013
(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.heliyon.2023.e14724
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37057050; ● Summary page in Scopus @ Elsevier: 2-s2.0-85150788405

(徳島大学機関リポジトリ: 2011013, DOI: 10.1016/j.heliyon.2023.e14724, PubMed: 37057050, Elsevier: Scopus) Yoshiki Higa, Masahiro Hiasa, Hirofumi Tenshin, Emiko Nakaue, Mariko Tanaka, SooHa Kim, Motosumi Nakagawa, Sou Shimizu, Kotaro Tanimoto, Jumpei Teramachi, Takeshi Harada, Asuka Oda, Masahiro Oura, Kimiko Sogabe, Tomoyo Hara, Ryohei Sumitani, Tomoko Maruhashi, Hiroki Yamagami, Itsuro Endo, Toshio Matsumoto, Eiji Tanaka and Masahiro Abe :
The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2.,
Antioxidants, 12, 1, 2023.

(要約): Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in purine catabolism that acts as a novel regulator of adipogenesis. In pathological states, xanthine oxidoreductase activity increases to produce excess reactive oxygen species (ROS). The nuclear factor erythroid 2-related factor 2 (Nrf2) is a critical inducer of antioxidants, which is bound and repressed by a kelch-like ECH-associated protein 1 (Keap1) in the cytoplasm. The Keap1-Nrf2 axis appears to be a major mechanism for robust inducible antioxidant defenses. Here, we demonstrate that febuxostat, a xanthine oxidase inhibitor, alleviates the increase in adipose tissue mass in obese mouse models with a high-fat diet or ovariectomy. Febuxostat disrupts in vitro adipocytic differentiation in adipogenic media. Adipocytes appeared at day 7 in absence or presence of febuxostat were 160.8 ± 21.2 vs. 52.5 ± 12.7 (p < 0.01) in 3T3L1 cells, and 126.0 ± 18.7 vs. 55.3 ± 13.4 (p < 0.01) in 10T1/2 cells, respectively. Adipocyte differentiation was further enhanced by the addition of hydrogen peroxide, which was also suppressed by febuxostat. Interestingly, febuxostat, but not allopurinol (another xanthine oxidase inhibitor), rapidly induced the nuclear translocation of Nrf2 and facilitated the degradation of Keap1, similar to the electrophilic Nrf2 activator omaveloxolone. These results suggest that febuxostat alleviates adipogenesis under oxidative conditions, at least in part by suppressing ROS production and Nrf2 activation. Regulation of adipocytic differentiation by febuxostat is expected to inhibit obesity due to menopause or overeating.
(徳島大学機関リポジトリ): ● Metadata: 2011068
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/antiox12010133
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36670994; ● Summary page in Scopus @ Elsevier: 2-s2.0-85146779366

(徳島大学機関リポジトリ: 2011068, DOI: 10.3390/antiox12010133, PubMed: 36670994, Elsevier: Scopus) Taiki Hori, Saya Yasui, Minae Hosoki, Hiroki Yamagami, Toshiki Otoda, Tomoyuki Yuasa, Kenichi Aihara, Makoto Takishita, Akihiko Yokohama, Mitusharu Ueda, Masahiro Abe and Shingen Nakamura :
Systemic amyloidosis associated with non-IgM type paraprotein with lymphoplasmacytic lymphoma,
International Journal of Myeloma, 13, 2, 7-12, 2023.

(徳島大学機関リポジトリ): ● Metadata: 2011339
(出版サイトへのリンク): ● Publication site (DOI): 10.57352/ijm.13.2_7
(文献検索サイトへのリンク): ● Search Scopus @ Elsevier (DOI): 10.57352/ijm.13.2_7

(徳島大学機関リポジトリ: 2011339, DOI: 10.57352/ijm.13.2_7) 堀太貴, Saya Yasui, Minae Hosoki, 山上紘規, 乙田敏城, 湯浅智之, 粟飯原賢一, Makoto Takishita, 安倍正博, 中村信元 :
初発時にCMVとHHV-6の再活性化と頭蓋内多発腫瘤を認めた成人T細胞白血病リンパ腫,
臨床血液, 64, 4, 283-289, 2023年.

(要約): (ATLL cells were 79% in flow cytometry), and the protein level was 244 mg/dl; moreover, the examination revealed a positive result for human herpesvirus 6 DNA. Despite herpesvirus genus treatment and modified LSG15 therapy combined with intrathecal chemotherapy, the patient became comatose and died on day 21 of hospitalization. A better understanding of the pathogenesis of ATLL, and the involvement with the central nervous system is needed along with the development of standard treatment.
(キーワード): 男性 (male) / Adult / Humans / Middle Aged / Leukemia-Lymphoma, Adult T-Cell / Herpesvirus 6, Human / Human T-lymphotropic virus 1 / Lymphoma / Cytomegalovirus Infections
(徳島大学機関リポジトリ): ● Metadata: 2011342
(出版サイトへのリンク): ● Publication site (DOI): 10.11406/rinketsu.64.283
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37121773; ● Search Scopus @ Elsevier (PMID): 37121773; ● Search Scopus @ Elsevier (DOI): 10.11406/rinketsu.64.283

(徳島大学機関リポジトリ: 2011342, DOI: 10.11406/rinketsu.64.283, PubMed: 37121773) Tomoyo Hara, Ryoko Uemoto, Akiko Sekine, Yukari Mitsui, Shiho Masuda, Hiroki Yamagami, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Yasumasa Ikeda, Itsuro Endo, Soichi Honda, Katsuhiko Yoshimoto, Akira Kondo, Toshiaki Tamaki, Toshio Matsumoto, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara :
Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus.,
Journal of Atherosclerosis and Thrombosis, 2022.

(要約): Multiple regression analysis including confounding factors showed that plasma HCII activity independently contributed to decreases in FIB-4 index (p<0.001), NFS (p<0.001) and APRI (p=0.004). In addition, logistic regression analysis for the prevalence of advanced hepatic fibrosis defined by the cutoff points of the clinical scores showed that plasma HCII activity was the sole and common negative factor for prevalence of advanced hepatic fibrosis (FIB-4 index: p=0.002, NFS: p=0.026 and APRI: p=0.012).
(徳島大学機関リポジトリ): ● Metadata: 2011020
(出版サイトへのリンク): ● Publication site (DOI): 10.5551/jat.63752
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244745; ● Search Scopus @ Elsevier (PMID): 36244745; ● Search Scopus @ Elsevier (DOI): 10.5551/jat.63752

(徳島大学機関リポジトリ: 2011020, DOI: 10.5551/jat.63752, PubMed: 36244745) Shingen Nakamura, Motoki Sugasaki, Masayoshi Souri, Hirohito Akazawa, Maiko Sogawa, Taiki Hori, Hiroki Yamagami, Makoto Takishita, Ken-ichi Aihara, Masahiro Abe, Atsushi Yasumoto, Eriko Morishita and Akitada Ichinose :
Autoimmune Acquired Factor XIII/13 Deficiency after SARS-CoV-2 mRNA Vaccination.,
Thrombosis and Haemostasis, 2022.

(徳島大学機関リポジトリ): ● Metadata: 2011100
(出版サイトへのリンク): ● Publication site (DOI): 10.1055/a-1863-7265
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35636450; ● Search Scopus @ Elsevier (PMID): 35636450; ● Search Scopus @ Elsevier (DOI): 10.1055/a-1863-7265

(徳島大学機関リポジトリ: 2011100, DOI: 10.1055/a-1863-7265, PubMed: 35636450)

MISC

研究者総覧に該当データはありませんでした。

総説・解説

研究者総覧に該当データはありませんでした。

講演・発表

Hiroki Yamagami, Tomoyo Hara, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara :
Analysis of clinical factors involved in AGE accumulation in people with type 2 diabetes,
IDF-WPR Congress 2023/15th Scientific Meeting of AASD, Jul. 2023. Yosuke Kaneko, Saya Yasui, Minae Hosoi, Akihiro Tani, Hiroki Yamagami, Hiroyasu Mori, Tomoyo Hara, Yukari Mitsui, Kiyoe Kurahashi, Sumiko Yoshida, Shingen Nakamura, Akio Kuroda, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Takeshi Soeki, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara :
Dehydroepiandrosterone sulfate and skeletal muscle disorders in patients with type 2 diabetes,
IDF-WPR Congress 2023/15th Scientific Meeting of AASD, Tokyo, Jul. 2023. Tomoyo Hara, Hiroki Yamagami, Y Mitsui, S Masuda, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara :
Clinical factors and glycemic control in Japanese patients with type 2 diabetes treated with 0.75 mg/ week Dulaglutide,
Kyoto, Jul. 2023. Tomoyo Hara, Hiroki Yamagami, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara :
Clinical factors and glycemic control in Japanese people with type 2 diabetes treated with weekly Dulaglutide at a dose of 0.75 mg,
IDF-WPR Congress 2023/15th Scientific Meeting of AASD, Jul. 2023. Minae Hosoki, Hiroki Yamagami, Taiki Hori, Saya Yasui, Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Masahiro Abe and Ken-ichi Aihara :
Pharmaceutical Influences on In-hospital Death in Patients with and Those without Diabetes at a Japanese General Hospital,
The 29th Scientific Meeting of the International Society of Hypertension, Oct. 2022. Shiho Masuda, Tomoyo Hara, Hiroki Yamagami, Mitsui Yukari, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Shingen Nakamura, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara :
Evaluation of Vascular Function for Prediction of Renal Prognosis in Japanese Patients with Lifestyle-Related Diseases,
The 29th Scientific Meeting of the International Society of Hypertension, Oct. 2022. Hiroki Yamagami, Saya Yasui, Minae Hosoki, Taiki Hori, Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Masahiro Abe and Ken-ichi Aihara :
Skin autofluorescence is associated with tubular injury represented by urinary excretion of liver-type fatty acid-binding protein in patients with diabetes,
American Diabetes Association 82nd Scientific Sessions, New Orleans, Jun. 2022. 谷口諭, 石津将, 鈴木麗子, 原倫世, 髙田千晶, 山上紘規, 遠藤逸朗, 黒田暁生, 松久宗英 :
糖尿病関連スティグマと病名変更意思に関連する因子の検討,
日本糖尿病学会中国四国地方会第63回総会, 2025年10月. 粟飯原賢一, 桝田志保, 原倫世, 山上紘規, 金子遥祐, 宮髙紘輔, 堀太貴, 湯浅智之, 中村信元, 遠藤逸朗 :
Estimated Pulse Wave Velocity(ePWV)による血管機能の臨床的妥当性評価,
第47回日本高血圧学会総会, 2025年10月. 粟飯原賢一, 坂尾佑佳子, 佐藤寛子, 細木美苗, 金子遥祐, 山上紘規, 原倫世, 乙田敏城, 湯浅智之, 中村信元, 遠藤逸朗 :
糖尿病の有無から見た当院における心不全死亡患者の臨床背景の検討,
第25回日本内分泌学会四国支部学術集会, 2025年9月. 坂尾佑佳子, 佐藤寛子, 細木美苗, 金子遥祐, 堀太貴, 山上紘規, 原倫世, 乙田敏城, 湯浅智之, 中村信元, 粟飯原賢一 :
糖尿病の有無から見た当院における心房細動合併死亡患者の臨床背景の検討,
第25回日本内分泌学会四国支部学術集会, 2025年9月. 粟飯原賢一, 原倫世, 山上紘規, 上元良子, 関根明子, 金子遥祐, 宮髙紘輔, 湯浅智之, 中村信元, 河野豊, 遠藤逸朗, 松岡賢市, 池田康将 :
ペマフィブラートは血管内皮機能障害の有無に関わらずマウスMASLD 病態を改善する,
第57回日本動脈硬化学会総会・学術集会, 2025年7月. 粟飯原賢一, 上元良子, 関根明子, 湯浅智之, 河野豊, 中村信元, 原倫世, 山上紘規, 金子遥祐, 宮髙紘輔, 松岡賢市, 遠藤逸朗, 池田康将 :
eNOS欠損MASLDモデルマウスにおけるペマフィブラートの影響に関する検討,
第98回日本内分泌学会学術総会, 2025年6月. 金子遥祐, 河田沙紀, 森建介, 細木美苗, 堀太貴, 宮髙紘輔, 辻誠士郎, 原倫世, 山上紘規, 乙田敏城, 湯浅智之, 河野豊, 中村信元, 黒田暁生, 遠藤逸朗, 松久宗英, 松岡賢市, 粟飯原賢一 :
代謝異常関連脂肪性肝疾患と赤血球Mean Corpuscular Volume の連関解析,
第68回日本糖尿病学会年次学術集会, 2025年5月. 八木萌香, 原倫世, 坂尾祐佳子, 佐藤寛子, 浅井孝仁, 安井沙耶, 山上紘規, 湯浅智之, 野村和弘, 黒田暁生, 中村信元, 遠藤逸朗, 松久宗英, 阪上浩, 松岡賢市, 粟飯原賢一 :
糖尿病関連腎臓病におけるフィブリノゲン/アルブミン比の意義に関する臨床的検討,
第68回日本糖尿病学会年次学術集会, 2025年5月. 粟飯原賢一, 原倫世, 山上紘規, 金子遥祐, 宮髙紘輔, 堀太貴, 湯浅智之, 森博康, 黒田暁生, 中村信元, 遠藤逸朗, 松岡賢市, 松久宗英 :
生体電気インピーダンス法による位相角の糖尿病関連腎臓病における臨床的意義,
第68回日本糖尿病学会年次学術集会, 2025年5月. 原倫世, 八木萌香, 坂尾祐佳子, 佐藤寛子, 浅井孝仁, 安井沙耶, 山上紘規, 湯浅智之, 黒田暁生, 中村信元, 遠藤逸朗, 松久宗英, 松岡賢市, 粟飯原賢一 :
糖尿病患者における可溶型DPP-4/CD26とMASLD病態の関連,
第68回日本糖尿病学会年次学術集会, 2025年5月. 原倫世, 八木萌香, 坂尾祐佳子, 佐藤寛子, 浅井孝仁, 安井沙耶, 山上紘規, 湯浅智之, 黒田暁生, 中村信元, 遠藤逸朗, 松久宗英, 松岡賢市, 粟飯原賢一, 柚山賀彦, 鴻山訓一, 楠宜樹, 大東真菜, 目黒周, 伊藤新, 岡田浩, 坂根直樹 :
2型糖尿病患者における可溶型DPP-4/CD26と代謝機能障害関連脂肪性肝疾患の関連,
第68回日本糖尿病学会年次学術集会, 2025年5月. 八木萌香, 原倫世, 坂尾祐佳子, 佐藤寛子, 浅井孝仁, 安井沙耶, 山上紘規, 湯浅智之, 野村和弘, 黒田暁生, 中村信元, 遠藤逸朗, 松久宗英, 阪上浩, 松岡賢市, 粟飯原賢一 :
糖尿病関連腎臓病におけるフィブリノゲン/アルブミン比の臨床的意義に関する検討,
第270回徳島医学会学術集会, 2025年2月. 安井沙耶, 清水一磨, 佐藤寛子, 坂尾祐佳子, 浅井孝仁, 原倫世, 山上紘規, 黒田暁生, 松久宗英, 遠藤逸朗 :
Hybrid Closed Loop導入により血糖管理が改善した高齢1型糖尿病の一例,
日本糖尿病学会中国四国地方会第62回総会, 2024年12月. 浅井孝仁, 清水一磨, 原倫世, 佐藤寛子, 坂尾祐佳子, 山上紘規, 金村亮, 黒田暁生, 松久宗英, 遠藤逸朗 :
早期に治療介入できた免疫関連有害事象による劇症1型糖尿病の1例,
日本糖尿病学会中国四国地方会第62回総会, 2024年12月. 安井沙耶, 清水一磨, 佐藤寛子, 坂尾祐佳子, 浅井孝仁, 原倫世, 山上紘規, 黒田暁生, 松久宗英, 遠藤逸朗 :
1-C-12 Hybrid Closed Loop 導入により血糖管理が改善した高齢1型糖尿病の一例,
日本糖尿病学会中国四国地方会第62回総会, 2024年12月. 粟飯原賢一, 湯浅智之, 中村信元, 山上紘規, 原倫世, 遠藤逸朗 :
搬送時心肺停止・死亡転帰患者における糖尿病の有無から見た臨床的背景の検討,
日本糖尿病学会中国四国地方会第62回総会, 2024年12月. 坂尾祐佳子, 原倫世, 佐藤寛子, 浅井孝仁, 安井沙耶, 山上紘規, 三井由加里, 桝田志保, 倉橋清衛, 遠藤逸朗 :
妊娠中の高血圧を契機に異時性両側褐色細胞腫と診断した1例,
第34回臨床内分泌代謝Update, 2024年11月. 粟飯原賢一, 湯浅智之, 中村信元, 村井純平, 岡本恵暢, 金子遥祐, 森建介, 細木美苗, 堀太貴, 河田沙紀, 辻誠士郎, 安井沙耶, 山上紘規, 原倫世, 乙田敏城, 遠藤逸朗 :
来院時心肺停止・死亡転帰患者の臨床背景における糖尿病有無の影響に関する検討,
第24回日本内分泌学会四国支部学術集会, 2024年9月. 秋澤聡秀, 原倫世, 坂尾祐佳子, 佐藤寛子, 浅井孝仁, 安井沙耶, 山上紘規, 添木武, 遠藤逸朗 :
高クロール血症を契機に診断に至った市販鎮痛薬による慢性ブロム中毒の1例,
第269回徳島医学会学術集会, 2024年7月. 粟飯原賢一, 三宅南帆, 辻誠士郎, 原倫世, 山上紘規, 中村信元, 乙田敏城, 湯浅智之 :
AI計測による上腕二頭筋断面積・筋輝度比と動脈硬化指標に関わるパイロット研究,
第56回日本動脈硬化学会総会・学術集会, 2024年7月. 原倫世, 横田海友, 清水一磨, 浅井孝仁, 山上紘規, 三井由加里, 桝田志保, 倉橋清衛, 乙田敏城, 湯浅智之, 黒田暁生, 遠藤逸朗, 松久宗英, 粟飯原賢一 :
心血管疾患リスクを有する患者における可溶型DPP-4/CD26と動脈硬化指標との連関解析,
第56回日本動脈硬化学会総会, 2024年7月. 原倫世, 横田海友, 清水一磨, 浅井孝仁, 山上紘規, 三井由加里, 桝田志保, 倉橋清衛, 乙田敏城, 湯浅智之, 黒田暁生, 遠藤逸朗, 松久宗英, 粟飯原賢一 :
糖尿病患者における可溶型DPP-4/CD26と動脈硬化指標との関連,
第67日本糖尿病学会学術集会, 2024年5月. 遠藤裕美, 原倫世, 清水一磨, 吉田麻衣子, 浅井孝仁, 山上紘規, 金村亮, 倉橋清衛, 遠藤逸朗 :
早期に治療介入できた免疫関連有害事象による1型糖尿病の1例,
第268回徳島医学会学術集会, 2024年3月. 原倫世, 清水一磨, 浅井孝仁, 吉田麻衣子, 山上紘規, 三井由加里, 倉橋清衛, 乙田敏城, 湯浅智之, 黒田暁生, 遠藤逸朗, 松久宗英, 粟飯原賢一 :
2型糖尿病患者の非アルコール性脂肪性肝疾患における尿中可溶性ウロキナーゼ型プラスミノーゲン活性化受容体の臨床的意義,
第38回日本糖尿病合併症学会, 2023年10月. 清水一磨, 山上紘規, 原倫世, 答島悠貴, 浅井孝仁, 三井由加里, 倉橋清衛, 松久宗英, 遠藤逸朗 :
診断に7年間を要したTSH産生下垂体micro adenomaの一例,
第33回臨床内分泌代謝Update, 2023年10月. 原倫世, 山上紘規, 三井由加里, 倉橋清衛, 中村信元, 乙田敏城, 湯浅智之, 遠藤逸朗, 粟飯原賢一 :
2 型糖尿病患者における血圧・血糖管理目標達成下での腎糸球体・尿細管障害のリスク因子の検討,
第45回日本高血圧学会総会, 2023年9月. 三宅南帆, 辻誠士郎, 河田沙紀, 原倫世, 山上紘規, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 :
2 型糖尿病患者における推定塩分摂取量に関連する臨床因子の検討,
第45回日本高血圧学会総会, 2023年9月. 山上紘規, 原倫世, 答島悠貴, 浅井孝仁, 三井由加里, 倉橋清衛, 乙田敏城, 湯浅智之, 黒田暁生, 遠藤逸朗, 松久宗英, 安倍正博, 粟飯原賢一 :
2型糖尿病患者のSkin autofluorscenceを規定する因子の検討,
第96回日本内分泌学会学術総会, 2023年6月. 山上紘規, 原倫世, 答島悠貴, 浅井孝仁, 三井由加里, 倉橋衛清, 乙田敏城, 湯浅智之, 黒田暁生, 遠藤逸朗, 松久宗英, 安倍正博, 粟飯原賢一 :

2 型糖尿病患者の AGEs 蓄積に関わる臨床的因子の解析, 2023年5月. 答島悠貴, 原倫世, 浅井孝仁, 山上紘規, 三井由加里, 倉橋衛清, 乙田敏城, 湯浅智之, 黒田暁生, 遠藤逸朗, 松久宗英, 粟飯原賢一 :
当院におけるインスリングラルギン/リキシセナチド(iGlarLixi)導入症例の臨床背景および効果の検討,
第66回日本糖尿病学会年次学術集会, 2023年5月. 山上紘規, 原倫世, 答島悠, 浅井孝, 三井由加里, 倉橋清衛, 乙田敏城, 湯浅智之, 黒田暁生, 遠藤逸朗, 松久宗英, 安倍正博, 粟飯原賢一 :
2型糖尿病患者のAGEs蓄積に関わる臨床的因子の解析,
第66回日本糖尿病学会年次学術集会, 2023年5月. 答島悠貴, 原倫世, 浅井孝, 山上紘規, 三井由加里, 倉橋清衛, 乙田敏城, 湯浅智之, 黒田暁生, 遠藤逸朗, 松久宗英, 粟飯原賢一 :
当院におけるインスリングラルギン/リキシセナチド (iGlarLixi)導入症例の臨床背景および効果の検討,
第66回日本糖尿病学会年次学術集会, 2023年5月. 原倫世, 答島悠貴, 浅井孝仁, 山上紘規, 三井由加里, 倉橋清衛, 乙田敏城, 湯浅智之, 黒田暁生, 遠藤逸朗, 松久宗英, 粟飯原賢一 :
糖尿病患者における腎糸球体および尿細管障害特異的なリスク因子の臨床的検討,
第66回日本糖尿病学会年次学術集会, 2023年5月. 答島悠貴, 原倫世, 浅井孝仁, 山上紘規, 三井由加里, 倉橋清衛, 吉田守美子, 黒田暁生, 松久宗英, 福本誠二, 松久宗英, 安倍正博 :
首下がりを契機に診断に至ったCushing病の一例,
内科学会第127回四国地方会, 2022年12月. 答島悠貴, 三井由加里, 浅井孝仁, 原倫世, 山上紘規, 倉橋清衛, 吉田守美子, 遠藤逸朗, 黒田暁生, 安倍正博, 松久宗英 :
レパグリニドとクロピドグレルの併用による遷延性低血糖を認めた一例,
日本糖尿病学会中国四国地方会第60回総会, 2022年11月. 中村信元, 堀太貴, 谷彰浩, 細木美苗, 安井沙耶, 宮田好裕, 山上紘規, 滝下誠, 粟飯原賢一 :
新型コロナワクチン接種後にvaccine-induced immune thrombotic thrombocytopeniaを疑われた症例,
日本老年医学会雑誌, 59, 4, 594, 2022年10月. 答島悠貴, 原倫世, 浅井孝仁, 山上紘規, 三井由加里, 倉橋清衛, 吉田守美子, 遠藤逸朗, 福本誠二 :
低ALP血症を契機として，ALPL遺伝子解析を行い診断に至った成人型低ホスファターゼ血症の一例,
第22回日本内分泌学会四国支部学術集会, 2022年9月. 原倫世, 浅井孝仁, 答島悠貴, 山上紘規, 三井由加里, 倉橋清衛, 吉田守美子, 福本誠二, 遠藤逸朗 :
授乳中にPTHrP上昇による高Ca血症を呈した一例,
第22回日本内分泌学会四国支部学術集会, 2022年9月. 三井由加里, 黒田暁生, 原倫世, 山上紘規, 倉橋清衛, 吉田守美子, 遠藤逸朗, 安倍正博, 松久宗英 :
持続皮下インスリン注入療法下 1 型糖尿病合併妊娠における分娩直後のインスリン投与設定変更の提案,
第22回日本糖尿病インフォマティクス学会年次学術集会, 2022年8月. 細木美苗, 山上紘規, 安井沙耶, 堀太貴, 中村信元, 乙田敏城, 湯浅智之, 粟飯原賢一 :
当院10年間における死亡患者の年齢・死因および併存合併症における糖尿病と治療薬剤の影響,
第22回日本糖尿病インフォマティクス学会年次学術集会, 2022年8月. 堀太貴, 中村信元, 谷彰浩, 細木美苗, 安井沙耶, 宮田好裕, 山上紘規, 辻誠士郎, 粟飯原賢一, 滝下誠 :
初発時にヘルペスウイルス属の再活性化と中枢浸潤を伴い急速に悪化した成人T細胞白血病リンパ腫の1例,
第126回日本内科学会四国地方会, 2022年6月. Shingen Nakamura, Taiki Hori, Minae Hosoki, Saya Yasui, Hiroki Yamagami, 赤澤啓人, 滝下誠 and Ken-ichi Aihara :
FXIII/13,
第126回日本内科学会四国地方会, Jun. 2022. 中村信元, 堀太貴, 細木美苗, 安井沙耶, 山上紘規, 答島章公, 滝下誠, 粟飯原賢一 :
血液疾患，自己免疫疾患における新型コロナワクチン接種後の抗体獲得能の検討,
感染症学雑誌, 96, 130, 2022年3月.

(キーワード): *血液疾患(薬物療法) *ウイルス抗体 *自己免疫疾患(薬物療法) *予防接種 *COVID-19ワクチン(治療的利用) ヒト中年(45∼64) 高齢者(65∼79) 高齢者(80∼) 男女

山上紘規, 中村信元, 細木美苗, 堀太貴, 安井沙耶, 粟飯原賢一, 答島章公, 滝下誠 :
自己免疫疾患における新型コロナワクチンによる抗体獲得能の検討,
日本内科学会雑誌, 111, Suppl., 218, 2022年2月.

(キーワード): Azathioprine(治療的利用) Methotrexate(治療的利用) Steroids(治療的利用) *関節炎-乾癬性(薬物療法) *関節リウマチ(薬物療法) *ウイルス抗体 *予防接種 Janus Kinase Inhibitors(治療的利用) COVID-19(予防,薬物療法) *COVID-19ワクチン(治療的利用) ヒト中年(45∼64) 高齢者(65∼79) 高齢者(80∼) 男女

堀太貴, 中村信元, 谷彰浩, 細木美苗, 安井沙耶, 宮田好裕, 山上紘規, 答島章公, 粟飯原賢一, 滝下誠 :
血液疾患患者における新型コロナウイルスワクチン接種による抗体獲得能の検討,
日本内科学会雑誌, 111, Suppl., 220, 2022年2月.

(キーワード): コロナウイルス感染症(予防,薬物療法) *ウイルスワクチン(治療的利用) *血液疾患 *ウイルス抗体肺炎-ウイルス性(予防,薬物療法) *予防接種 COVID-19(予防,薬物療法) *COVID-19ワクチン(治療的利用) ヒト成人(19∼44) 中年(45∼64) 高齢者(65∼79) 高齢者(80∼) 男女

堀太貴, 中村信元, 金子遥祐, 安井沙耶, 山上紘規, 粟飯原賢一, 滝下誠 :
1,
第124回日本内科学会四国地方会, 2021年5月.

研究会・報告書: 研究者総覧に該当データはありませんでした。

特許: 研究者総覧に該当データはありませんでした。
作品: 研究者総覧に該当データはありませんでした。
補助金・競争的資金: 研究者番号（01033026）による検索

その他: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2026年4月8日更新

専門分野・研究分野: 研究者総覧に該当データはありませんでした。
所属学会・所属協会: 研究者総覧に該当データはありませんでした。
委員歴・役員歴: 研究者総覧に該当データはありませんでした。
受賞: 研究者総覧に該当データはありませんでした。
活動: 研究者総覧に該当データはありませんでした。

更新

Ｊグローバル

Jグローバル最終確認日: JグローバルAPIで取得できませんでした。
氏名（漢字）: JグローバルAPIで取得できませんでした。
氏名（フリガナ）: JグローバルAPIで取得できませんでした。
氏名（英字）: JグローバルAPIで取得できませんでした。
所属機関: JグローバルAPIで取得できませんでした。

リサーチマップ

researchmap最終確認日: リサーチマップAPIで取得できませんでした。
氏名（漢字）: リサーチマップAPIで取得できませんでした。
氏名（フリガナ）: リサーチマップAPIで取得できませんでした。
氏名（英字）: リサーチマップAPIで取得できませんでした。
プロフィール: リサーチマップAPIで取得できませんでした。
登録日時: リサーチマップAPIで取得できませんでした。
更新日時: リサーチマップAPIで取得できませんでした。
アバター画像URI: リサーチマップAPIで取得できませんでした。
ハンドル: リサーチマップAPIで取得できませんでした。
eメール: リサーチマップAPIで取得できませんでした。
eメール（その他）: リサーチマップAPIで取得できませんでした。
携帯メール: リサーチマップAPIで取得できませんでした。
性別: リサーチマップAPIで取得できませんでした。
没年月日: リサーチマップAPIで取得できませんでした。
所属ID: リサーチマップAPIで取得できませんでした。
所属: リサーチマップAPIで取得できませんでした。
部署: リサーチマップAPIで取得できませんでした。
職名: リサーチマップAPIで取得できませんでした。
学位: リサーチマップAPIで取得できませんでした。
学位授与機関: リサーチマップAPIで取得できませんでした。
URL: リサーチマップAPIで取得できませんでした。
科研費研究者番号: リサーチマップAPIで取得できませんでした。
Google Analytics ID: リサーチマップAPIで取得できませんでした。
ORCID ID: リサーチマップAPIで取得できませんでした。
その他の所属ID: リサーチマップAPIで取得できませんでした。
その他の所属名: リサーチマップAPIで取得できませんでした。
その他の所属部署: リサーチマップAPIで取得できませんでした。
その他の所属職名: リサーチマップAPIで取得できませんでした。
最近のエントリー: リサーチマップAPIで取得できませんでした。
Read会員ID: リサーチマップAPIで取得できませんでした。
経歴: リサーチマップAPIで取得できませんでした。
受賞: リサーチマップAPIで取得できませんでした。
Misc: リサーチマップAPIで取得できませんでした。
論文: リサーチマップAPIで取得できませんでした。
講演・口頭発表等: リサーチマップAPIで取得できませんでした。
書籍等出版物: リサーチマップAPIで取得できませんでした。
研究キーワード: リサーチマップAPIで取得できませんでした。
研究分野: リサーチマップAPIで取得できませんでした。
所属学協会: リサーチマップAPIで取得できませんでした。
担当経験のある科目: リサーチマップAPIで取得できませんでした。
その他: リサーチマップAPIで取得できませんでした。
Works: リサーチマップAPIで取得できませんでした。
特許: リサーチマップAPIで取得できませんでした。
学歴: リサーチマップAPIで取得できませんでした。
委員歴: リサーチマップAPIで取得できませんでした。
社会貢献活動: リサーチマップAPIで取得できませんでした。

更新

研究者番号: KAKEN APIで取得できませんでした。

所属（現在）: KAKEN APIで取得できませんでした。

所属（過去の研究課題 情報に基づく）*注記: KAKEN APIで取得できませんでした。

審査区分/研究分野: KAKEN APIで取得できませんでした。

キーワード: KAKEN APIで取得できませんでした。

研究課題研究成果共同研究者

「研究課題をさがす」で表示
テキスト（CSV）で出力

テキスト（CSV）で出力

注目研究はありません。

研究者を探す

山上 紘規

Ｊグローバル

リサーチマップ

山上紘規